BST:H3AA

Stock Analysis Report

Executive Summary

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Biostage's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: H3AA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

13.1%

H3AA

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

83.2%

H3AA

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: H3AA exceeded the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: H3AA exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

H3AAIndustryMarket
7 Day13.1%11.2%7.3%
30 Day19.7%-5.3%-17.9%
90 Day97.6%-21.9%-25.8%
1 Year83.2%83.2%-4.9%-5.1%-15.1%-17.7%
3 Yearn/a17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Biostage's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biostage undervalued compared to its fair value and its price relative to the market?

28.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate H3AA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate H3AA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: H3AA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: H3AA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate H3AA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: H3AA is overvalued based on its PB Ratio (27.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Biostage forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biostage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Biostage performed over the past 5 years?

8.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: H3AA is currently unprofitable.

Growing Profit Margin: H3AA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: H3AA is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare H3AA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: H3AA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: H3AA has a negative Return on Equity (-766.37%), as it is currently unprofitable.


Next Steps

Financial Health

How is Biostage's financial position?


Financial Position Analysis

Short Term Liabilities: H3AA's short term assets ($1.5M) exceed its short term liabilities ($918.0K).

Long Term Liabilities: H3AA's short term assets ($1.5M) exceed its long term liabilities ($23.0K).


Debt to Equity History and Analysis

Debt Level: H3AA is debt free.

Reducing Debt: H3AA had no debt 5 years ago.


Balance Sheet

Inventory Level: H3AA has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if H3AA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: H3AA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if H3AA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Biostage's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate H3AA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate H3AA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if H3AA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if H3AA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of H3AA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average board tenure


CEO

Yu Hong (46yo)

no data

Tenure

Mr. Yu Hong has been Principal Executive Officer at Biostage, Inc. since March 22, 2020. Mr. Yu has been President of Biostage, Inc. since May 29, 2018. Mr. Yu has a depth of experience in cross-border bus ...


Board Members

NamePositionTenureCompensationOwnership
Joseph Vacanti
Co-Chairman of Scientific Advisory Board4.33yrsno datano data
Stephen Badylak
Co-Chairman of Scientific Advisory Boardno datano datano data
Jeffrey Young
Independent Director1.33yrsUS$28.01k0.29% $90.2k
James Shmerling
Independent Director2yrsUS$40.18kno data
Charles Cox
Member of Scientific Advisory Board2yrsno datano data
Jason Chen
Chairman of the Board2yrsUS$42.92k0.42% $129.9k
Christine Finck
Member of Scientific Advisory Board2.17yrsno datano data
Wei Zhang
Independent Director1.83yrsUS$37.16kno data
Ting Li
Independent Director1.33yrsUS$28.01kno data

2.0yrs

Average Tenure

57yo

Average Age

Experienced Board: H3AA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 79.8%.


Top Shareholders

Company Information

Biostage, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biostage, Inc.
  • Ticker: H3AA
  • Exchange: BST
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$34.082m
  • Listing Market Cap: US$30.739m
  • Shares outstanding: 8.52m
  • Website: https://biostage.com

Number of Employees


Location

  • Biostage, Inc.
  • 84 October Hill Road
  • Suite 11
  • Holliston
  • Massachusetts
  • 1746
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BSTGOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2013
H3AABST (Boerse-Stuttgart)YesCommon SharesDEEURApr 2013

Biography

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company’s Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient’s own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 00:07
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.